Short-course therapy of gemifloxacin effective against pneumococcal pneumonia in mice

Journal of Chemotherapy

Volumn 18, Issue 6, 2006, Pages 634-640

  Bast, Darrin James ^a,b   Dresser, L ^a,c   Duncan, C L ^a   Walker, S E ^c,d   Mandell, L A ^a,e   Low, D E ^a,b   De Azavedo, J C S ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

Fluoroquinolone; Murine; Pneumonia; Resistance; Short course

Indexed keywords

GEMIFLOXACIN; LEVOFLOXACIN; PROTEIN PARC; QUINOLONE DERIVATIVE;

ANIMAL EXPERIMENT; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SENSITIVITY; IN VIVO STUDY; LOBAR PNEUMONIA; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; STREPTOCOCCUS PNEUMONIAE;

EID: 33845971884     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2006.18.6.634     Document Type: Article

References (35)

1. Public Health Agency of Canada and Canadian Committee on Antibiotic Resistance. National policy conference on antibiotic resistance on antibiotic resistance, 5-7 October, 2002: Summary of Proceedings. Can Commun Dis Rep 2003; 29:153-64.
2. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis 2000; 31 (2):383-421.
3. Mandell LA, Bartlett JG, Dowell SF, File TM, Jr., Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37 (11):1405-33.
4. Fuller JD, Low DE. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin Infect Dis 2005; 41 (1):118-21.
5. Powis J, McGeer A, Green K et al. In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002. Antimicrob Agents Chemother 2004; 48 (9):3305-11.
6. Richter SS, Heilmann KP, Beekmann SE, Miller NJ, Rice CL, Doern GV. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations. Clin Infect Dis 2005; 40 (2):225-35.
7. Hooton TM, Levy SB. Antimicrobial resistance: a plan of action for community practice. Am Fam Physician 2001; 63 (6):1087-98.
8. Gin AS, Zhanel GG. Antimicrobial resistance. Can Pharm J 2001; 6:2-6.
9. Conly J. Antimicrobial resistance in Canada. CMAJ 2002; 167 (8):885-91.
10. Guillemot D, Carbon C, Balkau B et al. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 1998; 279 (5):365-70.
11. File TM, Jr. A new dosing paradigm: high-dose, short-course fluoroquinolone therapy for community-acquired pneumonia. Clin Cornerstone 2003; Suppl 3:S21-S28.
12. O'Doherty B, Muller O. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group. Eur J Clin Microbiol Infect Dis 1998; 17 (12):828-33.
13. Schonwald S, Kuzman I, Oreskovic K et al. Azithromycin: single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome-a randomized study. Infection 1999; 27 (3):198-202.
14. Schrag SJ, Pena C, Fernandez J et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA 2001; 286 (1):49-56.
15. Tellier G, Chang JR, Asche CV, Lavin B, Stewart J, Sullivan SD. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days. Curr Med Res Opin 2004; 20 (5):739-47.
16. Levine JP. Rationale for appropriate selection of antimicrobial therapy in acute bacterial sinusitis. J Family Med Supplement 2003; October:S21-S31.
17. Dunbar LM, Wunderink RG, Habib MP et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003; 37 (6):752-60.
18. Dunbar LM, Khashab MM, Kahn JB, Zadeikis N, Xiang JX, Tennenberg AM. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr Med Res Opin 2004; 20 (4):555-63.
19. Morrissey I, George JT. Bactericidal activity of gemifloxacin and other quinolones against Streptococcus pneumoniae. J Antimicrob Chemother 2000; 45 Suppl 1:107-10.
20. Bast DJ, Yue M, Chen X et al. Novel murine model of pneumococcal pneumonia: use of temperature as a measure of disease severity to compare the efficacies of moxifloxacin and levofloxacin. Antimicrob Agents Chemother 2004; 48 (9):3343-8.
21. Musson DG, Birk KL, Kitchen CJ et al. Assay methodology for the quantitation of unbound ertapenem, a new carbapenem antibiotic, in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 783 (1):1-9.
22. Avery O, MacLeod CM, McCarty M. Studies of the chemical nature of the substance inducing transformation of pneumococcal types. J Exp Med 1944; 79:137-158.
23. Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF. Pharmacodynamics of Fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract Infections. Antimicrob Agents Chemother 2001; 45 (10):2793-7.
24. Bast DJ, Low DE, Duncan CL, et al. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance [In Process Citation]. Antimicrob Agents Chemother 2000;44: 3049-3054
25. Pan XS, Ambler J, Mehtar S, et al. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother 1996;40: 2321-2326
26. Perichon B, Tankovic J, Courvalin P. Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 1997;41: 1166-1167
27. Bhavnani SM, Andes DR. Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy 2005; 25 (5):717-40.
28. Goff DA. Short-duration therapy for respiratory tract infections. Ann Pharmacother 2004; 38 (9 Suppl):S19-S23.
29. Reyes H, Guiscafre H, Munoz O, Perez-Cuevas R, Martinez H, Gutierrez G. Antibiotic noncompliance and waste in upper respiratory infections and acute diarrhea. J Clin Epidemiol 1997; 50 (11):1297-304.
30. Hoppe JE, Blumenstock G, Grotz W, Selbmann HK. Compliance of German pediatric patients with oral antibiotic therapy: results of a nationwide survey. Pediatr Infect Dis J 1999; 18 (12):1085-91.
31. Niederman MS, Mandell LA, Anzueto A et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163 (7):1730-54.
32. Ruhe JJ, Hasbun R. Streptococcus pneumoniae bacteremia: duration of previous antibiotic use and association with penicillin resistance. Clin Infect Dis 2003; 36 (9):1132-8.
33. Lim S, Bast D, McGeer A, de Azavedo J, Low DE. Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Emerg Infect Dis 2003; 9 (7):833-7.
34. Azoulay-Dupuis E, Bedos JP, Mohler J et al. Activity of gemifloxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model. Antimicrob Agents Chemother 2005; 49 (3):1046-54.
35. Alkorta M, Gimenez MJ, Vicente D, Aguilar L, Perez-Trallero E. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point. Int J Antimicrob Agents 2005; 25 (2):163-7.